Assessment of abuse liability of Tramadol among experienced drug users: Double-blind crossover randomized controlled trial.

CONCLUSION: Tramadol has abuse potential (even in therapeutic doses) more than Placebo but less than or comparable to Buprenorphine.
PMID: 28059434 [PubMed - in process]

Source: Journal of Opioid Management - January 10, 2017 Category: Addiction Tags: J Opioid Manag Source Type: research